Cell>Point LLC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://cellpointweb.com
Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)
Phase 2
Not yet recruiting
- Conditions
- Coronary Artery Disease
- Interventions
- Diagnostic Test: 99mTc-Sestamibi
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Cell>Point LLC
- Target Recruit Count
- 60
- Registration Number
- NCT01899833
- Locations
- ๐บ๐ธ
Tom Hennebry, MD, Oklahoma City, Oklahoma, United States
A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Radiation: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2013-07-12
- Lead Sponsor
- Cell>Point LLC
- Target Recruit Count
- 2
- Registration Number
- NCT01778218
- Locations
- ๐บ๐ธ
Cardiovascular Imaging Technologies, Kansas City, Kansas, United States
A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Lung Cancer
- Interventions
- Drug: 18 F FDG followed by PET/CT imagingDrug: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Cell>Point LLC
- Target Recruit Count
- 154
- Registration Number
- NCT01394679
- Locations
- ๐บ๐ธ
Decatur Memorial Hospital, Decatur, Illinois, United States
Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Radiation: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)Radiation: 18 F fluorodeoxyglucose
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Cell>Point LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00865319
- Locations
- ๐บ๐ธ
Decatur Memorial Hospital Department of Radiology, Decatur, Illinois, United States
๐บ๐ธJohn Hopkins University, Baltimore, Maryland, United States
๐บ๐ธBaptist Health South Florida, Coral Gables, Florida, United States
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Radiation: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)Radiation: 18 F fluorodeoxyglucoseRadiation: Technetium 99m ethylenedicysteine-deoxyglucose
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Cell>Point LLC
- Target Recruit Count
- 4
- Registration Number
- NCT00864110
- Locations
- ๐บ๐ธ
Mayo Clinic, Division of Nuclear Medicine, Rochester, Minnesota, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
๐บ๐ธMontefiore Medical Center, Bronx, New York, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath